Good interview. Him emphasizing that Perceptive is in for the long haul, mentioning 3-5 years, makes me wonder if a buyout may not be so probable. I know all shareholders could choose to take the buyout in shares of the buying company but a diversified company like Medtronic may not provide the same upside as an independent Anteris. I may be reading too much into this but just my thoughts.
He also said that they have been diligently working on Nasdaq and it looks like the dual listing could happen Q3-Q4. And it sounds like commercialization in 2024. So with funds to go deep into next year, I'm guessing we'll see one more raise later next year, at hopefully a much higher price, before DurAVR sales begin provided the trials go as expected and no license or buyout deals happen. As I posted in the thread yesterday, once clinical trials are finished and we submit our application for final approval by the FDA, it could take 3/4 of a year for the FDA to act on it and give its approval to start selling valves. So if we finish trials by Q3 next year, we could possibly get approval in the summer of 2024.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)